Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $7.00 | Outperform | Oppenheimer |
| 12/17/2024 | $17.00 | Overweight | Cantor Fitzgerald |
| 5/10/2024 | $8.00 | Outperform | Leerink Partners |
| 4/11/2024 | $10.00 | Overweight | Piper Sandler |
| 3/28/2024 | $7.00 | Outperform | Raymond James |
8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
10-Q - Aquestive Therapeutics, Inc. (0001398733) (Filer)
8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval
Planned U.S. launch of Anaphylm™ in the first quarter of 2026, if approved by the FDA Advanced Anaphylm regulatory activities in Canada and the EUAdded clinical leadership to drive long-term successStrengthened balance sheet to support planned commercial launch execution of AnaphylmCompany to host investor call on November 6, 2025, at 8:00am ET WARREN, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the third quarter ended September 30, 2
Changes strategically aligned to support planned launch of Anaphylm™ (dibutepinephrine) Sublingual Film, if approved by the FDA, and to accelerate the Company's ongoing development initiatives Matthew Davis, M.D., RPh will join immediately as Chief Development OfficerGary Slatko, M.D., M.B.A, will become interim Chief Medical Officer Peter Boyd, M.B.A, has been promoted to Chief People Officer WARREN, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced changes to
WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that David Amsellem, Sr. Research Analyst at Piper Sandler, will host a live fireside chat with the Company's management team on November 6, 2025 at 12:00 p.m. ET. The discussion will focus on the Company's product candidate Anaphylm™ (dibutepinephrine) Sublingual Film, including regulatory progress and commercial readiness. Aquestive management team participants include Dan Barber, Chief Executive Office
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
Oppenheimer resumed coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $7.00
Cantor Fitzgerald initiated coverage of Aquestive Therapeutics with a rating of Overweight and set a new price target of $17.00
Leerink Partners initiated coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $8.00
WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced its expected addition to the broad-market Russell 3000® and Russell 2000® Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24, 2024. "We are honored that Aquestive is joining the Russell 3000 Index, which represents the 3,000 largest U.S. public
WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p
Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of ageAppointed Carl N. Kraus, M.D. as Chief Medical Officer WARREN, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on recent business developments and announced the appointment of Carl N. Kraus, M.D. as Chief Medical Officer of the Company. NDA Filing for Libervant for Pediatric PopulationAquestive submitted a N
Planned U.S. launch of Anaphylm™ in the first quarter of 2026, if approved by the FDA Advanced Anaphylm regulatory activities in Canada and the EUAdded clinical leadership to drive long-term successStrengthened balance sheet to support planned commercial launch execution of AnaphylmCompany to host investor call on November 6, 2025, at 8:00am ET WARREN, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the third quarter ended September 30, 2
WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended September 30, 2025 and provide an update on recent developments in its business after market close on Wednesday, November 5, 2025. Management will host a conference call for investors at 8:00 a.m. ET on Thursday, November 6, 2025. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A liv
FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDACompany accelerates Anaphylm global expansion strategy to Canada and the EUCompany to host investor call on August 12, 2025, at 8:00am ET WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the second quarter ended June 30, 2025, and provided a strategic business update. "The sec
SC 13G/A - Aquestive Therapeutics, Inc. (0001398733) (Subject)
SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)
SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)